Transplantation strategies for the management of patients with myelodysplastic syndromes

Journal of B.U.ON.

Volumn 14, Issue 4, 2009, Pages 551-564

  Meletis, J ^a   Terpos, E ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

Allogeneic stem cell transplantation; Autologous stem cell transplantation; Bone marrow transplantation; Myelodysplastic syndromes; Reduced conditioning allogeneic transplantation

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; AXITINIB; AZACITIDINE; BEVACIZUMAB; BORTEZOMIB; CLOFARABINE; CYCLOSPORIN; ETANERCEPT; FK 2228; IMATINIB; INFLIXIMAB; LENALIDOMIDE; LONAFARNIB; MCN 512; METHOTREXATE; MIDOSTAURIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VATALANIB; VORINOSTAT;

AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; GENETIC ASSOCIATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INFECTIOUS COMPLICATION; LYMPHOCYTE TRANSFER; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROGNOSIS; RECURRENCE RISK; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SURVIVOR; TREATMENT FAILURE; UMBILICAL CORD BLOOD;

HUMANS; MYELODYSPLASTIC SYNDROMES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 75149168936     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier D. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87: 743-745.
2. Aul C, Germing U, Gattermann, Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res 1998; 22: 93-100.
3. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 2001; 73: 405-410.
4. Catenacci DVT, Schiller GJ. Myelodysplastic syndromes: a comprehensive review. Blood Rev 2005; 19: 301-319.
5. Finch SC. Myelodysplasia and radiation. Rad Res 2004; 161: 603-606.
6. Nisse C, Haguenoer JM, Grandbastien B et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br J Haematol 2001; 112: 927-935.
7. Mundle S, Allampallam K, Rashid KA et al. Presence of activation-related m-RNA for EBV and CMV in the bone marrow of patients with myelodysplastic syndromes. Cancer Lett 2001; 164: 197-205.
8. Dalamaga M, Petridou E, Cook FE, Trichopoulos D. Risk factors for myelodysplastic syndromes: a case-control study in Greece. Cancer Cause Control 2002; 13: 603-608.
9. Rund D, Ben-Yehuda D. Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment. Hematology 2004; 9: 179-187.
10. McLaughlin P, Estey E, Glassman A et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005; 105: 4573-4575.
11. Parker JE, Mufti GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998; 101: 220-230.
12. Olney HJ, LeBeau MM. The cytogenetics of myelodysplastic syndromes. Best Practice Res Clin Haematol 2001 ; 14: 479-495.
13. Hellström-Lindberg E, Malcovati L. Supportive care, growth factors, and new therapies in myelodysplastic syndromes. Blood Rev 2008; 22: 75-91.
14. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
15. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of the hematologic malignancies report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
16. Greenberg P, Cox C, LeBeau MM et al. International prognostic scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
17. Greenberg PL, Bishop M, Deeg J et al. NCCN Practice Guidelines for Myelodysplastic Syndromes. Oncology 1998; 12(11A): 53-80.
18. Terpos E, Mougiou A, Kouraklis A et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002; 118: 174-180.
19. Kantarjian H, O'Brien S, Cortes J et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 2008; 113(7 Suppl): 1933-1952.
20. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-2440.
21. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacytidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005; 10: 176-182.
22. List A, Kurtin S, Roe DJ et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-457.
23. Galili N, Raza A. Immunomodulatory drugs in myelodysplastic syndromes. Expert Opin Investig Drugs 2006; 15: 805-813.
24. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndromes: outcomes analysis according to IPSS score. Leukemia 1998; 12(Suppl 1): 25-29.
25. Nevill TJ, Fung HC, Sheperd JD et al. Cytogenetic abnormalities in primary myelodysplastic syndromes are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998; 92: 1910-1917.
26. Runde V, de Witte T, Arnold R et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 255-261.
27. DeWitte T, Hermans J, Vossen J et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2000; 110: 620-630.
28. Cheson BD, Greenberg PL, Bennett JM et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
29. Deeg HJ, Shulman HM, Andersen JE et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndromes in patients 55 to 66 years of age. Blood 2000; 95: 1188-1194.
30. Wallen H, Gooley TA, Deeg HJ et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23: 3439-3446.
31. Sierra J, Perez WS, Rozman C et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004.
32. Arnold R, de Witte T, van Biezen A et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 1998; 21: 1213-1216.
33. Castro-Malaspina H, Harris RE, Gajewski J et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943-1951.
34. Deeg HJ, Storer B, Slattery JT et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201-1207.
35. Remberger M, Storer B, Ringden O, Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002; 29: 391 -397.
36. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
37. Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
38. Warlick ED, O'Donnell PV, Borowitz M et al. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res 2008; 32: 1439-1447.
39. Valcarcel D, Martino R, Caballero D et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577-584.
40. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586-2591.
41. Morris EC, Rebello P, Thomson KJ et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404-406.
42. Waller EK, Langston AA, Lonial S et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003; 9: 460-471.
43. Ho AY, Pagliuca A, Kenyon M et al. Reduced-intensity allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukaemia with multilineage dysplasia using fludarabine, busulfan and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616-1623.
44. Perez-Simon JA, Kottaridis PD, Martino R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
45. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
46. Malladi RK, Peniket AJ, Norton AE et al. Favourable outcome for patients with myeloid disorders treated with fludarabinemelphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. Eur J Haematol 2004; 73: 85-92.
47. Raiola AM, Van Lint MT, Lamparelli T et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 2000; 109: 716-721.
48. Martino R, Iacobelli S, Brand R et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836-846.
49. de Lima M, Anagnostopoulos A, Munsell M et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865-872.
50. Tauro S, Craddock C, Peggs K et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
51. Shimoni A, Hardan I, Shem-Tov N et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322-328.
52. Ingram W, Lim ZY, Mufti GJ. Allogeneic transplantation for myelodysplastic syndrome (MDS). Blood Rev 2006; 21: 61-71.
53. Hallemeier CL, Girgis MD, Blum WG et al. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 2006; 12: 749-757.
54. Couban S, Simpson DR, Barnett MJ et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531.
55. Nivison-Smith I, Bradstock KF, Szer J et al. Allogeneic haemopoietic cell transplants in Australia, 1996 - a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. Bone Marrow Transplant 2001; 28: 21-27.
56. Parreira A, Smith J, Hows JM et al. Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow. Clin Exp Immunol 1987; 67: 142-150.
57. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
58. Chakrabarti S, Avivi I, Mackinnon S et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 2002; 119: 1125-1132.
59. Laport GG, Sandmaier BM, Storer BE et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008; 14: 246-255.
60. Scott BL, Sandmaier BM, Storer B et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128-135.
61. Mijovic ADM, Sekhavat M, Czepulowski B, Mufti GJ. Do patients with low-grade myelodysplastic syndrome mobilise normal hemopoietic progenitors? Leuk Res 2001; 25: S1-S22.
62. Carella AM, Dejana A, Lerma E et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 1996; 95: 127-130.
63. Ducastelle S, Ades L, Gardin C et al. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Haematologica 2006; 91: 373-376.
64. de Witte T, Brand R, van Biezen A et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica 2006; 91: 750-756.
65. de Witte T, Suciu S, Brand R et al. Autologous stem cell transplantation in myelodysplastic syndromes. Semin Hematol 2007; 44: 274-277.
66. Rocha V, Labopin M, Sanz G et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukaemia. N Engl J Med 2004; 351: 2276-2285.
67. Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukaemia. N Engl J Med 2004; 351: 2265-2275.
68. Barker JN, Weisdorf DJ, DeFor TE et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003; 102: 1915-1919.
69. Sullivan KM, Storb R, Buckner CD et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828-834.
70. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
71. Depil S, Deconinck E, Milpied N et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 2004; 33: 531-534.
72. Shiobara S, Nakao S, Ueda M et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000; 26: 769-774.
73. de Lima, Bonamino M, Vasconcelos Z et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001; 27: 73-78.